CSCC 2019 e-Poster Presentations:

Interactive session with the authors of e-Poster presentations.

ID: 2 - Current status of laboratory reference intervals during pregnancy

Vilte Barakauskas

ID:1 7 - Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents
Mary Katheryn Bohn

ID: 29 - Expanding the reporting range of ferritin to facilitate the acute diagnosis of hemophagocytic lymphohistiocytosis: How high can we go?

Heather Paul

ID: 33 - Validation and evaluation of infliximab assay in IBD
Josko Ivica

ID: 30 - Pre-analytical contamination of pediatric urine drug screening samples with tributoxyethylphosphate (TBEP)
Heather Paul

ID: 45 - Impact of prevalence of hypocalcemia on the accuracy of albumin-adjusted calcium
Dana Bailey

ID: 19 - LPrevalence of confirmed human anti-animal antibody interference in the Beckman Coulter, Inc. (BCI) Access® luteinizing hormone (LH) assay

Sarah Delaney

ID: 25 - Enzyme-free and wash-free localized isothermal signal amplification for cell surface imaging

Ashley Newbigging

ID: 52 - Prospective evaluation of the Siemen’s thyroid-stimulating immunoglobulin (TSI) assay for diagnosis and prognosis of Graves’ disease

Jason Robinson

ID: 43 - Wine colored samples? Development of laboratory reporting guidelines for hydroxocobalamin (OHCob) interference in patients pulled from house fires

Josh Raizman

Question Title

* 1. Please Rate Each Session:

	Did Not Attend	Poor	Fair	Good	Very Good	Excellent
ID: 2 - Current status of laboratory reference intervals during pregnancy - Vilte Barakauskas	ID: 2 - Current status of laboratory reference intervals during pregnancy - Vilte Barakauskas Did Not Attend	ID: 2 - Current status of laboratory reference intervals during pregnancy - Vilte Barakauskas Poor	ID: 2 - Current status of laboratory reference intervals during pregnancy - Vilte Barakauskas Fair	ID: 2 - Current status of laboratory reference intervals during pregnancy - Vilte Barakauskas Good	ID: 2 - Current status of laboratory reference intervals during pregnancy - Vilte Barakauskas Very Good	ID: 2 - Current status of laboratory reference intervals during pregnancy - Vilte Barakauskas Excellent
ID: 17 - Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents - Mary Kathryn Bohn	ID: 17 - Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents - Mary Kathryn Bohn Did Not Attend	ID: 17 - Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents - Mary Kathryn Bohn Poor	ID: 17 - Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents - Mary Kathryn Bohn Fair	ID: 17 - Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents - Mary Kathryn Bohn Good	ID: 17 - Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents - Mary Kathryn Bohn Very Good	ID: 17 - Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents - Mary Kathryn Bohn Excellent
ID: 29 - Expanding the reporting range of ferritin to facilitate the acute diagnosis of hemophagocytic lymphohistiocytosis: How high can we go? - Heather Paul	ID: 29 - Expanding the reporting range of ferritin to facilitate the acute diagnosis of hemophagocytic lymphohistiocytosis: How high can we go? - Heather Paul Did Not Attend	ID: 29 - Expanding the reporting range of ferritin to facilitate the acute diagnosis of hemophagocytic lymphohistiocytosis: How high can we go? - Heather Paul Poor	ID: 29 - Expanding the reporting range of ferritin to facilitate the acute diagnosis of hemophagocytic lymphohistiocytosis: How high can we go? - Heather Paul Fair	ID: 29 - Expanding the reporting range of ferritin to facilitate the acute diagnosis of hemophagocytic lymphohistiocytosis: How high can we go? - Heather Paul Good	ID: 29 - Expanding the reporting range of ferritin to facilitate the acute diagnosis of hemophagocytic lymphohistiocytosis: How high can we go? - Heather Paul Very Good	ID: 29 - Expanding the reporting range of ferritin to facilitate the acute diagnosis of hemophagocytic lymphohistiocytosis: How high can we go? - Heather Paul Excellent
ID: 33 - Validation and evaluation of infliximab assay in IBD - Josko Ivica	ID: 33 - Validation and evaluation of infliximab assay in IBD - Josko Ivica Did Not Attend	ID: 33 - Validation and evaluation of infliximab assay in IBD - Josko Ivica Poor	ID: 33 - Validation and evaluation of infliximab assay in IBD - Josko Ivica Fair	ID: 33 - Validation and evaluation of infliximab assay in IBD - Josko Ivica Good	ID: 33 - Validation and evaluation of infliximab assay in IBD - Josko Ivica Very Good	ID: 33 - Validation and evaluation of infliximab assay in IBD - Josko Ivica Excellent
ID: 30 - Pre-analytical contamination of pediatric urine drug screening samples with tributoxyethylphosphate (TBEP) - Heather Paul	ID: 30 - Pre-analytical contamination of pediatric urine drug screening samples with tributoxyethylphosphate (TBEP) - Heather Paul Did Not Attend	ID: 30 - Pre-analytical contamination of pediatric urine drug screening samples with tributoxyethylphosphate (TBEP) - Heather Paul Poor	ID: 30 - Pre-analytical contamination of pediatric urine drug screening samples with tributoxyethylphosphate (TBEP) - Heather Paul Fair	ID: 30 - Pre-analytical contamination of pediatric urine drug screening samples with tributoxyethylphosphate (TBEP) - Heather Paul Good	ID: 30 - Pre-analytical contamination of pediatric urine drug screening samples with tributoxyethylphosphate (TBEP) - Heather Paul Very Good	ID: 30 - Pre-analytical contamination of pediatric urine drug screening samples with tributoxyethylphosphate (TBEP) - Heather Paul Excellent
ID: 45 - Impact of prevalence of hypocalcemia on the accuracy of albumin-adjusted calcium - Dana Bailey	ID: 45 - Impact of prevalence of hypocalcemia on the accuracy of albumin-adjusted calcium - Dana Bailey Did Not Attend	ID: 45 - Impact of prevalence of hypocalcemia on the accuracy of albumin-adjusted calcium - Dana Bailey Poor	ID: 45 - Impact of prevalence of hypocalcemia on the accuracy of albumin-adjusted calcium - Dana Bailey Fair	ID: 45 - Impact of prevalence of hypocalcemia on the accuracy of albumin-adjusted calcium - Dana Bailey Good	ID: 45 - Impact of prevalence of hypocalcemia on the accuracy of albumin-adjusted calcium - Dana Bailey Very Good	ID: 45 - Impact of prevalence of hypocalcemia on the accuracy of albumin-adjusted calcium - Dana Bailey Excellent
ID: 19 - Prevalence of confirmed human anti-animal antibody interference in the Beckman Coulter, Inc. (BCI) Access® luteinizing hormone (LH) assay - Sarah Delaney	ID: 19 - Prevalence of confirmed human anti-animal antibody interference in the Beckman Coulter, Inc. (BCI) Access® luteinizing hormone (LH) assay - Sarah Delaney Did Not Attend	ID: 19 - Prevalence of confirmed human anti-animal antibody interference in the Beckman Coulter, Inc. (BCI) Access® luteinizing hormone (LH) assay - Sarah Delaney Poor	ID: 19 - Prevalence of confirmed human anti-animal antibody interference in the Beckman Coulter, Inc. (BCI) Access® luteinizing hormone (LH) assay - Sarah Delaney Fair	ID: 19 - Prevalence of confirmed human anti-animal antibody interference in the Beckman Coulter, Inc. (BCI) Access® luteinizing hormone (LH) assay - Sarah Delaney Good	ID: 19 - Prevalence of confirmed human anti-animal antibody interference in the Beckman Coulter, Inc. (BCI) Access® luteinizing hormone (LH) assay - Sarah Delaney Very Good	ID: 19 - Prevalence of confirmed human anti-animal antibody interference in the Beckman Coulter, Inc. (BCI) Access® luteinizing hormone (LH) assay - Sarah Delaney Excellent
ID: 25 - Enzyme-free and wash-free localized isothermal signal amplification for cell surface imaging - Asjley Newbigging	ID: 25 - Enzyme-free and wash-free localized isothermal signal amplification for cell surface imaging - Asjley Newbigging Did Not Attend	ID: 25 - Enzyme-free and wash-free localized isothermal signal amplification for cell surface imaging - Asjley Newbigging Poor	ID: 25 - Enzyme-free and wash-free localized isothermal signal amplification for cell surface imaging - Asjley Newbigging Fair	ID: 25 - Enzyme-free and wash-free localized isothermal signal amplification for cell surface imaging - Asjley Newbigging Good	ID: 25 - Enzyme-free and wash-free localized isothermal signal amplification for cell surface imaging - Asjley Newbigging Very Good	ID: 25 - Enzyme-free and wash-free localized isothermal signal amplification for cell surface imaging - Asjley Newbigging Excellent
ID: 52 - Prospective evaluation of the Siemen’s thyroid-stimulating immunoglobulin (TSI) assay for diagnosis and prognosis of Graves’ disease - Jason Robinson	ID: 52 - Prospective evaluation of the Siemen’s thyroid-stimulating immunoglobulin (TSI) assay for diagnosis and prognosis of Graves’ disease - Jason Robinson Did Not Attend	ID: 52 - Prospective evaluation of the Siemen’s thyroid-stimulating immunoglobulin (TSI) assay for diagnosis and prognosis of Graves’ disease - Jason Robinson Poor	ID: 52 - Prospective evaluation of the Siemen’s thyroid-stimulating immunoglobulin (TSI) assay for diagnosis and prognosis of Graves’ disease - Jason Robinson Fair	ID: 52 - Prospective evaluation of the Siemen’s thyroid-stimulating immunoglobulin (TSI) assay for diagnosis and prognosis of Graves’ disease - Jason Robinson Good	ID: 52 - Prospective evaluation of the Siemen’s thyroid-stimulating immunoglobulin (TSI) assay for diagnosis and prognosis of Graves’ disease - Jason Robinson Very Good	ID: 52 - Prospective evaluation of the Siemen’s thyroid-stimulating immunoglobulin (TSI) assay for diagnosis and prognosis of Graves’ disease - Jason Robinson Excellent
ID: 43 - Wine colored samples? Development of laboratory reporting guidelines for hydroxocobalamin (OHCob) interference in patients pulled from house fires - Josh Raizman	ID: 43 - Wine colored samples? Development of laboratory reporting guidelines for hydroxocobalamin (OHCob) interference in patients pulled from house fires - Josh Raizman Did Not Attend	ID: 43 - Wine colored samples? Development of laboratory reporting guidelines for hydroxocobalamin (OHCob) interference in patients pulled from house fires - Josh Raizman Poor	ID: 43 - Wine colored samples? Development of laboratory reporting guidelines for hydroxocobalamin (OHCob) interference in patients pulled from house fires - Josh Raizman Fair	ID: 43 - Wine colored samples? Development of laboratory reporting guidelines for hydroxocobalamin (OHCob) interference in patients pulled from house fires - Josh Raizman Good	ID: 43 - Wine colored samples? Development of laboratory reporting guidelines for hydroxocobalamin (OHCob) interference in patients pulled from house fires - Josh Raizman Very Good	ID: 43 - Wine colored samples? Development of laboratory reporting guidelines for hydroxocobalamin (OHCob) interference in patients pulled from house fires - Josh Raizman Excellent

Question Title

* 2. Please assess the Sessions as a whole

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Sufficient time was allowed for audience participation/active learning	Sufficient time was allowed for audience participation/active learning Strongly Disagree	Sufficient time was allowed for audience participation/active learning Disagree	Sufficient time was allowed for audience participation/active learning Neutral	Sufficient time was allowed for audience participation/active learning Agree	Sufficient time was allowed for audience participation/active learning Strongly Agree
The facilities were satisfactory	The facilities were satisfactory Strongly Disagree	The facilities were satisfactory Disagree	The facilities were satisfactory Neutral	The facilities were satisfactory Agree	The facilities were satisfactory Strongly Agree
The session was free from commercial bias	The session was free from commercial bias Strongly Disagree	The session was free from commercial bias Disagree	The session was free from commercial bias Neutral	The session was free from commercial bias Agree	The session was free from commercial bias Strongly Agree
Overall, I would rate this Symposium as excellent	Overall, I would rate this Symposium as excellent Strongly Disagree	Overall, I would rate this Symposium as excellent Disagree	Overall, I would rate this Symposium as excellent Neutral	Overall, I would rate this Symposium as excellent Agree	Overall, I would rate this Symposium as excellent Strongly Agree

Question Title

* 3. As a result of attending these sessions, I am planning to:

a) Discuss the session with my colleagues

b) Pursue additional learning activities.

c) Complete a Personal Learning Project.

d) Not change my practice.

e) Change my practice.

Question Title

* 4. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Medical Expert

Communicator

Collaborator

Manager

Health Advocate

Scholar

Professional

CSCC 2019 e-Poster Presentations:

Interactive session with the authors of e-Poster presentations.

Question Title

* 1. Please Rate Each Session:

Question Title

* 2. Please assess the Sessions as a whole

Question Title

* 3. As a result of attending these sessions, I am planning to:

Question Title

* 4. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Question Title

* 6. General comments about individual speakers:

Question Title

* 7. What topics would you like to be addressed at future conferences to keep you up to date in your profession?